Develops advanced drug delivery technologies which enhance the effectiveness of new therapeutic agents, existing pharmaceutical products and prescription nutritional products.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Why get back in? The pipeline? Personally, the local obstetrics community's reaction here was/is that Makena was a pathetic attempt to manipulate the FDA, doctors, insurances and patients and I could see this leading to a backlash and blacklisting led by physicians, who in the US, are gatekeepers to pharmaceuticals. Unless KV demonstrates some value over the compounded product the pharmacist has been mixing on the bench for forever AND does some serious physician PR work (despite their altruism, doctors tend to hold grudges against those that arm twist them and profit unethically from their patients that were being served well ), I think the company may have bet the farm and lost big here.